Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03518112 |
Recruitment Status :
Completed
First Posted : May 8, 2018
Last Update Posted : June 11, 2021
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Philadelphia Chromosome Negative Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia | Biological: Blinatumomab Drug: Cyclophosphamide Drug: Cytarabine Drug: Dexamethasone Biological: Filgrastim Other: Laboratory Biomarker Analysis Drug: Leucovorin Calcium Drug: Mercaptopurine Drug: Methotrexate Biological: Pegfilgrastim Biological: Rituximab Drug: Vincristine Sulfate | Phase 2 |
PRIMARY OBJECTIVE:
I. To evaluate the combined effect of blinatumomab and mini-hyper-CVD (low-intensity chemotherapy) on event-free survival.
SECONDARY OBJECTIVES:
I. Evaluating other clinical efficacy endpoints (minimal residual disease [MRD] negativity, duration of response, the overall response rate [complete response (CR) + CR with inadequate count recovery (CRi)]) of the regimen occurred any time during the treatment.
II. Overall survival. III. Determining the safety of the combination regimen.
OUTLINE:
INDUCTION PHASE: Patients receive blinatumomab intravenously (IV) continuously on days 1-28 and dexamethasone orally (PO) or IV over 30 minutes on days -3 to day 0 and 7-10. Patients also receive filgrastim subcutaneously (SC) on days 1-42 or pegfilgrastim SC on days 1 and 25, cyclophosphamide IV over 3 hours twice daily (BID) on days -3 to -1, methotrexate intrathecally (IT) on day 2 and IV over 24 hours on day 22, cytarabine IT on day 7 and IV over 3 hours BID on days 23 and 24, and vincristine sulfate IV over 15 minutes on days 0 and 7. At the discretion of the treating physician, patients may receive rituximab IV over 4-6 hours on days -3, 0, 22 and 29, and leucovorin calcium IV over 15 minutes or PO 4 times daily (QID) for 8 doses.
CONSOLIDATION PHASE: Patients receive blinatumomab IV continuously on days 1-28 and dexamethasone PO or IV over 30 minutes on days 1-4 and 11-14. Patients also receive cyclophosphamide IV over 3 hours BID on days 1-3, vincristine sulfate IV over 15 minutes on days 1 and 11, filgrastim SC on days 1-4 and 22-42 or pegfilgrastim SC on day 5 and 25, methotrexate IT on day 2 and IV over 24 hours on day 22, cytarabine IT on day 7 and IV over 3 hours BID on days 23 and 24. At the discretion of the treating physician, patients may receive rituximab IV over 4-6 hours on days 1, 8, 22 and 29, and leucovorin calcium IV over 15 minutes or PO QID for 8 doses. Treatment repeats every 42 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE PHASE: Patients receive prednisone PO and vincristine sulfate IV over 15 minutes on days 1-5 of cycles 5-9, 7-11 and 13-24, and mercaptopurine PO BID on days 1-28 of cycles 1-5, 7-11, and 13-24. Patients also receive methotrexate PO once a week and blinatumomab IV continuously on days 1-28 of cycles 6 and 12. Cycles repeat every 28 days for up to 24 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) |
Actual Study Start Date : | April 18, 2018 |
Actual Primary Completion Date : | May 27, 2021 |
Actual Study Completion Date : | May 27, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (blinatumomab, combination chemotherapy)
See detailed description.
|
Biological: Blinatumomab
Given IV
Other Names:
Drug: Cyclophosphamide Given IV
Other Names:
Drug: Cytarabine Given IT or IV
Other Names:
Drug: Dexamethasone PO or IV
Other Names:
Biological: Filgrastim Given SC
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Drug: Leucovorin Calcium Given IV
Other Names:
Drug: Mercaptopurine Given PO
Other Names:
Drug: Methotrexate Given IT or IV
Other Names:
Biological: Pegfilgrastim Given SC
Other Names:
Biological: Rituximab Given IV
Other Names:
Drug: Vincristine Sulfate Given IV
Other Names:
|
- Event free survival (EFS) where events defined as no response, loss of response, or death [ Time Frame: From the first day of treatment assessed up to 2 years ]The median EFS time will be estimated by Bayesian posterior estimates, along with the 95% credible intervals. Will be estimated using the Kaplan-Meier method, and log rank test will be used to compare the differences in the time-to-event variables between subgroups (e.g. different patient characteristics).
- Minimal residual disease (MRD) negativity [ Time Frame: Up to 2 years ]Will be summarized using descriptive statistics, including means with standard deviations, or medians with ranges, histograms and box-plot.
- Duration of response [ Time Frame: From date on initial response assessed up to 2 years ]Defined as the number of days from the date of initial response (partial response [PR] or better) to the date of first documented disease progression/relapse or death. Will be estimated using the Kaplan-Meier method, and log rank test will be used to compare the differences in the time-to-event variables between subgroups (e.g. different patient characteristics).
- Overall response rate [ Time Frame: Up to 2 years ]defined as the percentage of patients achieving complete response (CR) or CR with inadequate count recovery (CRi). Will be estimated along with 95% confidence interval. Overall response rate will be compared between subgroups (e.g. different patient characteristics) by Fisher's exact test and minimal residual disease difference will be assessed by Wilcoxon rank test, respectively.
- Overall survival [ Time Frame: Time from the first day of treatment assessed up to 2 years ]defined as the time from treatment start till death or last follow-up. Will be estimated using the Kaplan-Meier method, and log rank test will be used to compare the differences in the time-to-event variables between subgroups (e.g. different patient characteristics).
- Incidence of adverse events [ Time Frame: Up to 2 years ]Toxicity will be reported by type, frequency and severity. Highest toxicity grades per patient per course will be tabulated for selected adverse events and laboratory measurements.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with first or second relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)
- Performance status =< 3 (Eastern Cooperative Oncology Group [ECOG] scale)
- Total serum bilirubin =< 2 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the principal investigator (PI)
- Alanine aminotransferase (ALT) =< 3 x ULN, unless due to the underlying leukemia approved by the PI
- Aspartate aminotransferase (AST) =< 3 x ULN unless due to the underlying leukemia approved by the PI
- Signed informed consent
- Women of childbearing potential (WOCBP) or male subjects with a partner who is WOCBP must agree to use contraception during the study, if sexually active
Exclusion Criteria:
- Patients with Philadelphia chromosome (Ph)-positive ALL or Burkitt leukemia
- Active, uncontrolled central nervous system (CNS) leukemia involvement
- Active serious infection not controlled by oral or intravenous antibiotics
- Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year
- Known hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
- Active grade III-V cardiac failure as defined by the New York Heart Association criteria
- Patients with a cardiac ejection fraction (as measured by either multi-gated acquisition [MUGA] or echocardiogram) < 40%
- Prior history of treatment with blinatumomab
- Treatment with any investigational antileukemic agents or chemotherapy agents in the last two weeks, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator
- Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception; women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months; in addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03518112
United States, Texas | |
M D Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Elias Jabbour | M.D. Anderson Cancer Center |
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT03518112 |
Other Study ID Numbers: |
2017-0127 NCI-2018-00737 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2017-0127 ( Other Identifier: M D Anderson Cancer Center ) |
First Posted: | May 8, 2018 Key Record Dates |
Last Update Posted: | June 11, 2021 |
Last Verified: | June 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Philadelphia Chromosome Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Translocation, Genetic Chromosome Aberrations Pathologic Processes Calcium, Dietary Leucovorin |
Folic Acid Cytarabine Dexamethasone Dexamethasone acetate Cyclophosphamide Rituximab Methotrexate Vincristine Mercaptopurine Blinatumomab Antineoplastic Agents, Immunological Muromonab-CD3 Antibodies Immunoglobulins Antibodies, Monoclonal |